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Abstract
Exposure to hepatitis C virus (HCV) typically results in chronic infection that leads to progressive liver disease ranging from
mild inflammation to severe fibrosis and cirrhosis as well as primary liver cancer. HCV triggers innate immune signaling
within the infected hepatocyte, a first step in mounting of the adaptive response against HCV infection. Persistent
inflammation is strongly associated with liver tumorigenesis. The goal of our work was to investigate the initiation of the
inflammatory processes triggered by HCV viral proteins in their host cell and their possible link with HCV-related liver
cancer. We report a dramatic upregulation of the lymphotoxin signaling pathway and more specifically of lymphotoxin-b in
tumors of the FL-N/35 HCV-transgenic mice. Lymphotoxin expression is accompanied by activation of NF-kB, neosynthesis
of chemokines and intra-tumoral recruitment of mononuclear cells. Spectacularly, IKKb inactivation in FL-N/35 mice
drastically reduces tumor incidence. Activation of lymphotoxin-b pathway can be reproduced in several cellular models,
including the full length replicon and HCV-infected primary human hepatocytes. We have identified NS5B, the HCV RNA
dependent RNA polymerase, as the viral protein responsible for this phenotype and shown that pharmacological inhibition
of its activity alleviates activation of the pro-inflammatory pathway. These results open new perspectives in understanding
the inflammatory mechanisms linked to HCV infection and tumorigenesis.
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Introduction
Persistent HCV infection affects about 170 million people
worldwide [1] and is one of the most common causes of chronic
liver disease [2]. Infected individuals typically suffer from chronic
liver inflammation that can last several decades and lead to
progressive fibrotic liver that can culminate in hepatic cirrhosis
and hepatocellular carcinoma (HCC) (for review see [3]).
Inflammation is the first step of the immune response against
HCV infection and as such is beneficial to the host. However, in
most cases, the infection is not resolved, fuelling the long-term
persistent inflammation, with its many deleterious effects (for
review see [4]), including the onset and progression of cancer.
Inflammatory cytokines and chemokines are key molecular players
in these processes, both by direct signaling, by recruiting further
immune cells and by orchestrating production of reactive oxygen
species, with their associated risk of inducing DNA mutations (for
review see [5,6].
Although the molecular mechanisms underlying HCV-associ-
ated liver cancer remain poorly understood (for review see [7]),
there is no doubt that persistent liver inflammation increases the
risk of HCC development by providing diverse mediators that
perturb tissue homeostasis, including reactive oxygen species [8]
and aberrant expression of cytotoxic cytokines [9,10,11]. Interest-
ingly, it has been reported that several HCV proteins, namely
core, NS3 and NS5A, can induce expression of pro-inflammatory
cytokines [12,13,14] through yet to be identified mechanisms.
Lymphotoxin-a (LTa) and lymphotoxin-b (LTb), two members
of the tumor necrosis factor (TNF) superfamily, are necessary for
organogenesis and maintenance of lymphoid tissues [15,16]. LTa
is soluble whereas LTb contains a transmembrane domain. In
consequence, LT exist both as soluble homotrimers (LTa3) that
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engage TNF receptor (TNFR) 1 and TNFR2 and the herpes virus
entry mediator receptor (HVEM) and as membrane-bound hetero-
trimers (LTa1b2 or LTa2b1) that activate LTbR [17,18]. LTbR
acts through activation of canonical and alternative NF-kB signaling
to induce the expression of a subset of chemokines (for review see
[19], [20]. It has been shown that HCV infection is associated with
increased hepatic LT expression both in vivo and in vitro [10,21] and
that HCV core protein can interact with the cytoplasmic domain of
LTbR, thus stimulating the NF-kB pathways [22,23]. Moreover,
HCV replication in vitro depends on components of the LTbR
pathway [24] while an ectopic LT expression in transgenic mice
gives rise to liver inflammation and HCC [21]. However, the
molecular mechanisms responsible for switching on LT expression in
the HCV-infected hepatocytes have not been elucidated.
Here we report that tumors of HCV transgenic mice (FL-N/35
lineage) exhibit constitutively active LTbR and NF-kB signaling.
Inhibition of the canonical NF-kB pathway through hepatocyte-
specific deletion of Ikkb [25] fully protects the animals from HCV-
linked HCC. We further show that the viral RNA polymerase,
NS5B, either alone or in the context of the full complement of viral
proteins, is sufficient to induce expression of LT and NF-kB -
dependant expression of its downstream target, CXCL10. Our data
identify NS5B, recently shown to induce cytokine expression in
hepatocytes through an RNA-dependent mechanism [26], as an
inducer of the LTbR pathway, and specifically of lymphotoxin beta
expression. These findings suggest that inhibitors of lymphotoxin
signaling together with viral RNA polymerase inhibitors can be used
to reduce HCV induced liver inflammation and HCC risk
Results
Immune cell infiltration of FL-N/35 tumors
FL-N/35 transgenic mice have a hepatocyte-targeted expression
of the entire open reading frame (ORF) of the genotype 1b HCV,
leading to expression of low levels of the full complement of viral
proteins in the liver [27,28]. In this model, HCV protein expression
renders male mice at risk for liver tumorigenesis after one year of
age [27]. Despite previous reports of lack of overt inflammation in
the FL-N/35 animals, and because a vast majority of human HCV-
linked HCC develops in necroinflammatory livers, we decided to
reinvestigate a possible more subtle liver inflammatory phenotype of
the FL-N/35 mice. In accordance with previously published
observations [27,29], prior to tumor development we detected only
rare inflammatory foci, and no significant increase in either the
number of inflammatory cells or proinflammatory cytokine
expression in FL-N/35 livers compared to wild type mice (Figures
S1 and S2). In contrast, multiple cellular infiltrations were present in
FL-N/35 tumors (Figure 1A). The infiltrates were polymorphic and
more specifically contained macrophages as well as B and T
lymphocytes (Figure 1B).
Lymphotoxin expression in FL-N/35 tumors
It has been reported that activation of inflammatory signaling
triggered by LTbR gives rise to hepatocellular tumors in mice
[21]. To investigate whether this pathway is instrumental in HCV-
related tumorigenesis in FL-N/35 animals, we studied the
expression of several of its key components. Quantitative RT-
PCR analysis showed a dramatic increase in LTb expression in all
FL-N/35 tumors analyzed (n= 10). LTa expression was also
increased in most tumors, albeit to a lesser extent, while LTbR
levels did not differ significantly between tumoral and peritumoral
samples (Figure 2A). Tumor-specific augmentation of LTb
expression was confirmed at the protein level (Figure 2B), while
immunofluorescence staining showed that hepatocytes were the
major source of this cytokine (Figure 2C). Strong LTb expression
was specific to HCV-linked liver tumors, as it was not increased in
N-myc driven tumors of WHV/N-myc2 transgenic mice [30]
(Figures 3A and 3C). Reinforcing this result, there was no increase
in LT expression in rare spontaneous liver tumors arising in
animals of the same genetic background as FL-N/35 mice
(Figures 3B and 3C). In addition to LTb, several pro-inflammatory
cytokines, notably TNFa, IL6 and Il1b (Figure S3) were mildly,
but significantly increased in HCV-related tumors, while changes
of interferons a and b expression (Figure S4) did not reach
statistical significance. Altogether, these results suggest a specific
link between LTb and HCV-related tumorigenesis.
Increased LT expression has been reported in many human
hepatic pathologies, including HCC of different etiologies [10,21].
We have confirmed these observations by showing significant
increase of LTb in tumoral and peri-tumoral samples of patients
carrying HCC of either HCV or alcohol related cirrhosis (Figure
S5A). Importantly, hepatocytes are a major source of this cytokine
in the diseased liver (Figure S5B).
NF-kB signaling is activated in FL-N/35 tumors
LTbR signals through canonical and alternative NF-kB
pathways to induce expression of several pro-inflammatory
chemokines that act to recruit immune cells (for review see
[18,20]). To determine if LTb upregulation is associated with
activation of NF-kB signaling in the FL-N/35 tumors, we first
investigated RelA (p65) localization in livers of tumor-bearing
animals. Nuclear translocation of p65, indicative of canonical NF-
kB activation, was detected in over 60% of tumoral hepatocytes,
while less than 5% of peritumoral cells were positive in this assay,
suggesting that NF-kB signaling was indeed activated in cells
expressing LTb (Figure 4A). In contrast, NF-kB was not activated
in spontaneous liver tumors (Figure 4A). Next we assayed for
activation of the alternative NF-kB signaling by visualizing
cleavage of p100 into the mature p52 form of NF-kB. In
agreement with previous reports of LT mode of action [19], the
alternative NF-kB signaling was also activated in the HCV-related
mouse tumors (Figure 4B). Moreover, the majority of tested
tumors showed a strong increase of expression of CXCL10
(Figure 4C and 4D), an inflammatory chemokine downstream of
LTbR (for review see [31]; [32]). Altogether these data suggest
that increased LTb expression in HCV-linked tumors leads to
activation LTbR pathway of proinflammatory signaling.
Author Summary
Hepatitis C affects nearly 200 million people worldwide. It
results from the failure of the immune system to control the
hepatitis C virus (HCV) replication and spread, leading to
progressive liver disease that can culminate in fibrosis,
cirrhosis and cancer. The inflammatory cells that infiltrate
the diseased liver functionally contribute to fibrotic disease
and cancer development by the release of potent soluble
mediators that regulate cell survival and proliferation,
angiogenesis, tissue remodelling, metabolism and genomic
integrity. The goal of our work was to study themechanisms
of the initiation of the inflammatory process linked to HCV
infection. We have shown that the presence of a single viral
protein, namely NS5B, the RNA dependent RNA polymerase,
promotes pro-inflammatory signaling. Moreover, inhibition
of this pathway in HCV transgenic mice fully protects the
animals from HCV-linked liver cancer. Our study contributes
to a better understanding of the inflammatory mechanisms
linked to HCV infection and thereby to tumorigenesis.
HCV Polymerase Activates Lymphotoxin Signaling
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IKKb-dependent NF-kB signaling is required for FL-N/35
tumorigenesis
While the role of canonical and alternative NF-kB signaling in
liver carcinogenesis is complex (for review see [11]; [25]; [33]), it
was suggested that the canonical NF-kB pathway is instrumental in
relaying the oncogenic signal provided by LTbR activation [21].
This signal depends on the IKKb catalytic subunit of the IkB kinase
complex [34]. To determine if this scenario is operational in HCV-
linked tumors, we crossed FL-N/35 mice with hepatocyte-specific
IKKb-deficient animals (IKKbDhep) [35]. As previously reported
[27], HCV transgenic mice carrying wild type Ikkb alleles are
tumor-prone, with 30% of males developing hepatocellular
adenoma and carcinoma after 12 months of age (Figure 5A). In
the genetic background compatible with HCV-related liver
tumorigenesis ([28] and our unpublished data), we routinely observe
spontaneous liver tumors in about 5% of over one year old males.
Strikingly, in FL-N/35/IKKbDhep mice, in which Ikkb deletion was
confirmed by western blot (Figure 5B) and which express similar
levels of HCV RNA that the control FL-N/35 animals (Figure 5C),
the frequency of tumor formation was indistinguishable from wt
non-transgenic males (Figure 5A) and, similarly to spontaneous
lesions, the single hepatic tumor that appeared in this cohort was
negative for LTb expression (not shown). Thus, invalidation of
IKKb-dependent canonical NF-kB signaling blocks HCV-related
liver tumorigenesis in the FL-N/35 model.
Molecular mechanism of LT induction by HCV proteins
To investigate the mechanism of LTb induction by HCV
proteins, we turned to a full-length HCV replicon propagated in
Huh7 human hepatoma cells: the Nneo/C-5B model [36]. The
replicon-containing cells expressed significantly more LTa, LTb
and, to a lesser extent, LTbR, compared to the parental Huh7
cells (Figure 6A). As in tumors from HCV transgenic mice,
expression of CXCL10 was also induced in the Nneo/C-5B cells,
suggesting that pro-inflammatory signaling cascade was activated.
Moreover, productive infection of Huh-7.5.1 cells with JFH1-
derived Con1/C3 HCV [37,38] gave rise to a similar pattern of
inflammatory signaling (Figure 6B).
While the HCV proteins are organized in an endoplasmic
reticulum-associated multiprotein complex [39], isolated viral
proteins maintain some activities that may be relevant to the
physiopathology of viral infection. To determine if LT pathway
activation could be related to a specific viral protein, we
established stable polyclonal Huh7 populations in which expres-
sion of individual HCV proteins was driven by a heterologous
promoter. Out of the five proteins tested (core, NS3, NS4A, NS5A
and NS5B), only NS5B, the viral RNA-dependent RNA
polymerase, reproduced the increase of LTb expression
(Figure 7A, 7D, Figure S6). This result was not a peculiarity of
the cellular model used, since it was confirmed in HepaRG-
tetNS5B cells, which are human immature hepatocytes closely
resembling primary cells [40] with doxycycline-regulated expres-
sion of NS5B (Figure 7B). Interestingly, in contrast to most models
used in this study, which are based on HCV proteins of the 1b
genotype, the infectious JFH-1-based model and the HepaRG-
tetNS5B express the genotype 2a NS5B, demonstrating that the
observed phenotype is not restricted to a single viral isolate.
Next we asked if the enzymatic activity of NS5B was required
for LTb upregulation. Huh7 cells constitutively expressing NS5B
were treated with 29-C-Methylcytidine, a pharmacological inhib-
itor of RNA-dependent RNA polymerase activity [41,42,43].
While this treatment had no effect on NS5B expression, it
Figure 1. Immune cell infiltration in FL-N/35 tumors. Histological sections of FL-N/35 livers tumors. (A) Haematoxylin and eosin staining. Arrow
indicates cellular infiltration. (B) Immunohistochemical staining of macrophages (MAC2), T lymphocyte (CD3) and B lymphocyte (B220). Arrows
indicate positive cells. T: tumor, P: peritumoral.
doi:10.1371/journal.ppat.1003234.g001
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abrogated upregulation of LTb, LTa and CXCL10 (Figure 7C
and 7E). Similarly, expression of a catalytically inactive mutant,
NS5B G317V, [44] in HepaRG cells did not activate LTb
synthesis (Figure 7D). Importantly, enzymatic activity of NS5B was
also required for activation of both the canonical and the
alternative NF-kB signaling (Figure 7 F and G).
Finally, we studied the functional relationship between NF-kB
and LT signaling and their downstream effector, the CXCL10
chemokine. We used shRNAs to silence expression of either the
p65 NF-kB subunit or LTb in Huh7-NS5B cells. Silencing of
either of these genes fully abrogated CXCL10 induction by NS5B
(Figures 7H, Figure S7). Taken together, our results strongly
support the notion that NS5B activity, in the absence of viral
RNA, gives rise to increased lymphotoxin expression, which in
turn activates a NF-kB-dependent pro-inflammatory signaling.
Discussion
Persistent HCV infection is a major cause of chronic liver
disease. In particular chronic inflammation, resulting from
continuous immune response against infected hepatocytes, is
associated with necro-inflammatory changes, liver fibrosis and
cirrhosis and HCC development (for review see [45]). The
molecular mechanisms involved in initiation and in fuelling of this
process, sometimes over very long periods, are still incompletely
understood (for review see [7]). In this report we show an
upregulation of a pro-inflammatory cytokine, LTb, and its
downstream targets, NF-kB and CXCL10, in HCV-related
tumors and in several cellular models based on expression of
HCV proteins. The most spectacular alteration of this inflamma-
tory signaling pathway was a very strong upregulation of LTb
expression in nine out of ten liver tumors of transgenic mice with
liver-targeted expression of HCV proteins. The one exception
(animal 440 in Fig. 2) had high levels of LTb transcripts and
protein both in the tumoral and peri-tumoral liver samples,
suggestive of an ongoing inflammation unrelated to HCV.
Augmented LTb expression was also observed in several
hepatocyte cell lines harboring the totality or a subset of HCV
proteins or solely NS5B, the RNA dependent RNA polymerase.
However, it was not detectable in non-tumoral regions of FL-N/
35 transgenic livers despite the presence of detectable viral RNA
transcripts. In this context it is noteworthy that while efficient
cytokine induction by NS5B requires high levels of the enzyme
[26], the expression of HCV proteins is typically over 10–100 fold
Figure 2. Lymphotoxin expression in FL-N/35 tumors. RNA and proteins extracted from FL-N/35 tumors and corresponding peritumoral areas
were analyzed by RT-qPCR and by immunoblotting, respectively. (A) RT-qPCR analysis of LTa, LTb and LTbR mRNA normalized to 18S ribosomal RNA.
Numbers below bars identify the animals analyzed. Results were analyzed by Wilcoxon matched-pairs signed rank test (*p,0.05, **p,0.005). (B)
Protein expression analyzed by immunoblotting with an anti-LTb antibody (left panel) and corresponding quantification (right panel). Expression of a
housekeeping gene, GAPDH, served as a loading control. Numbers correspond to animals analyzed. PT = peritumoral, T = tumoral tissue. (C)
Immunofluorescence analysis of LTb expression in peritumoral and tumoral areas of a typical tumor-bearing liver. DAPI staining was used to visualize
nuclei.
doi:10.1371/journal.ppat.1003234.g002
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higher in cellular models compared to the transgenic mouse livers
analyzed here [46], probably accounting for lack of LT expression
in the livers of the FL-N/35 animals. Interestingly, the level of viral
RNA in mouse tumors is comparable to that found in peritumoral
liver (data not shown). Although we cannot exclude possible
variations of NS5B protein expression between the non-tumoral
and the tumoral tissues, as well as within individual cells, our data
suggest that LT activation might not initiate tumorigenesis, but
rather contributes to tumor progression in this animal model.
Indeed, strong LTb expression in 100% of tumors together with
complete abrogation of HCV-linked tumorigenesis in animals
invalidated for canonical NF-kB signaling, which acts both as an
upstream activator and a downstream effector of LT pathway,
prompt us to speculate that an autoregulatory loop involving LT
and NF-kB might exist in HCV-linked HCC.
A previous report described strong activation of several
additional inflammatory cytokines in mouse livers with orthotopic
expression of NS5B [26]. In our experimental set up we detected
only a mild, albeit significant, expression of TNFa, Il6 and Il1b
and no significant increase in type I interferon in the mouse
tumors. This apparent discrepancy between the two studies is once
again most likely due to very different levels of expression of NS5B,
which in our experimental model is at least an order of magnitude
lower and probably closer to the physiological levels present in the
majority of chronic hepatitis C patients.
LT exists predominantly as a membrane bound heterotrimer of
LTa and LTb subunits with LTa1-b2 stoichiometry, which binds
with high affinity to LTbR [17]. Importantly, increased expression
of LTb was previously described in patients, in the context of
chronic hepatitis C-associated cirrhosis and HCC [10,21,47],
supporting physiopathological relevance of our data.
LTbR activation gives rise to expression of several chemokines
through canonical and alternative NF-kB signaling (for review see
[19]. Interestingly, in the FL-N/35 HCV transgenic mouse model,
where the tumors show strong activation of both LT and NF-kB,
abrogation of the canonical NF-kB pathway by hepatocyte-specific
IKKb ablation, led to a dramatic decrease in tumor incidence,
arguing for a major role of NF-kB in promoting tumorigenesis in
the context of HCV. However, the role of NF-kB in liver
carcinogenesis is complex, as it inhibits cell death-promoted
tumorigenesis [25,48,49], while promoting inflammation-driven
tumor-formation in Mdr2-deficient [33] and in LT-transgenic
mice [21] and in xenografts of human HCC [50].
It is perhaps not surprising that NF-kB, with its many possible
downstream effectors and activities [51] is endowed with both pro-
and anti-tumorigenic activities that are dominant under different
Figure 3. Lymphotoxins are not deregulated either in N-myc-driven or in spontaneous liver tumors. (A) RT-qPCR analysis of LTa, LTb
and LTbR mRNA expression in N-myc tumors and wild type mice from the same breeding. Quantification was performed on three different mice. (B)
RT-qPCR analysis of LTa, LTb and LTbR mRNA expression in spontaneous tumors. 18S RNA expression was used as a reference. (C) Western blot
analysis of LTb in spontaneous and N-myc tumors. FLN 445 tumor was used as positive control. Expression of a housekeeping gene, GAPDH, served
as a loading control. Numbers identify the animals analyzed.
doi:10.1371/journal.ppat.1003234.g003
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physiological contexts. However, it is noteworthy that our data,
linking HCV with LT and NF-kB signaling in the context of
hepatocellular tumorigenesis, are in full agreement with HCC
development triggered by ectopic LT expression [21].
We have shown that increased LT expression in hepatocytes
expressing viral proteins has functional consequences in that it
leads to synthesis of CXCL10. This C-X-C chemokine is
expressed by hepatocytes in chronic hepatitis C
[21,48,52,53,54]. It is induced by LTbR via NF-kB [31,55] and
is considered as one of the main chemoattractors for tumor-
infiltrating immune cells (for review see [56]). It is thus tempting to
speculate that CXCL10, induced by HCV viral proteins via LTbR
and NF-kB could initiate liver recruitment of hematopoietic cells
as well as intratumoral cellular infiltrates.
Mechanistically, we have shown that NS5B, the viral RNA-
dependent RNA polymerase, is sufficient to activate the LT
pathway and therefore upregulate chemokine production. Al-
though physiologically NS5B is part of a multiprotein replication
complex, the isolated protein also has enzymatic activity [57].
Moreover, NS5B interacts with several cellular proteins, including
transcriptional regulators such as Rb [58,59], RNA cellular
helicases such as p68, which modulates RNA structures and is
involved in RNA splicing, processing, transcription and translation
[60] and eIF4AII, an RNA-helicase translation initiation factor [61].
Furthermore, a recent study described the role of the RNA sequence
encoding NS5B as a pathogen associated molecular pattern (PAMP)
following RNase L cleavage [62]. While all these interactions might
participate in triggering inflammatory signaling downstream of
NS5B, our data indicating that the enzymatic activity of NS5B is
essential for induction of LT expression suggest that the molecular
mechanism of LTbR activation by HCV relies on RNA synthesis,
most probably from cellular RNA templates [63]. Further biochem-
ical experiments are needed to formally demonstrate this point.
These uncertainties notwithstanding, the discovery of LT
pathway activation by NS5B and the fact that pharmacological
inhibition of its enzymatic activity alleviates the pro-inflammatory
phenotype, open new perspectives for understanding the inflam-
matory mechanisms linked to HCV infection. In particular these
results suggest that LTbR signaling could be an interesting target
for therapies aimed at curbing HCV-related liver inflammation,
known to be a major risk factor for severe hepatic pathologies,
including HCC.
Figure 4. NF-kB activation in FL-N/35 tumors. (A) Immunohistochemical staining of p65 NF-kB subunit (brown) in FL-N/35 and spontaneous
tumors. Arrows point to nuclear localization of p65, indicative of NF-kB activation. Nuclei are counterstained in blue. Quantification of p65
translocation is presented as mean+/2 SEM of three independent experiments (**p,0.001). (B) p100, p52 protein levels in tumors and peritumoral
regions of FL-N/35 mice livers. Processing of p100 to p52 is indicative of noncanonical NF-kB signaling. (C). RT-qPCR analysis of CXCL10 mRNA
expression in FL-N/35 tumors and corresponding peritumoral areas. (D) CXCL10 protein levels and corresponding quantification in tumors and
peritumoral regions of FL-N/35 mice. PT = peritumoral, T: tumor. Numbers identify animals analyzed.
doi:10.1371/journal.ppat.1003234.g004
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Materials and Methods
Animals
FL-N/35 transgenic animals [27] and IkkbF/F:Alb-Cre (referred
to as IkkbDhep) [35] were bred and maintained according to the
French institutional guidelines. Twelve to twenty month-old males
were used in these experiments.
Patient tissue samples
HCC and corresponding nontumoral tissues were obtained
from resected specimens from patients treated at the University
Hospitals of Bordeaux and Montpellier, France. Small pieces from
tumoral and nontumoral livers were snap frozen in liquid nitrogen
and stored at 280uC until use. In parallel, samples were fixed and
processed for immunohistochemistry. Informed consent was
obtained according to the institutional regulations.
Cell culture and treatments
Huh7 cells were cultured in DMEM supplemented with 10%
fetal bovine serum, 100 mg/ml streptomycin and 100 U/ml
penicillin. 400 mg/ml of G418 were added to cells harboring the
Nneo/C-5B replicons and 2 mg/ml of puromycin to Huh7-NS5B
cells. HepaRG and HepaRG-NS5B tetracycline-inducible cells
were grown in William’s E medium supplemented with 10% fetal
calf serum, 5 mg/ml insulin, 5.1025 M hydrocortisone hemisucci-
nate, 100 units/ml penicillin, and 100 mg/ml streptomycin. When
appropriate, cells were treated for 24 hours with 6 mg/ml of the
NS5B inhibitors 29-C-Methylcytidine from Santa Cruz Biotech-
nology (Heidelberg, Germany) or with 0.5 mg/ml of doxycycline
from Sigma (St. Louis, MO).
Generation of stably transfected cell lines
NS5B cDNA sequences from genotype 1b was subcloned in
Myc-tagged pMSCV retroviral vectors as previously described
[64]. ShRNA coding sequences were cloned in pSIREN-RetroQ
(Clontech, Palo Alto, CA). Plasmids were transfected into 293T
cells with jetPEI (Polyplus, Illkirch, France), according to the
manufacturer’s instructions. Supernatants were used to infect Huh
7 cells. Infection efficiencies of 80% were routinely obtained.
Puromycin (2 mg/ml) and hygromycin (150 mg/ml) were used as
selection agents.
The sense and antisense strands of shRNAs were :
LTb : 59- atccgcctctactgtctcgtcggctattcaagagatagccgacgagacag-
tagaggcttttttctcgagg -39
39- gcggagatgacagagcagccgataagttctctatcggctgctctgtcatctcc-
gaaaaaagagctccttaa -59
P65 (RelA) : 59- gatccggccttaatagtagggtaagttttcaagagaaacttaccc-
tactattaaggccttttttctcgag -39
Figure 5. Invalidation of the canonical NF-kB signaling reduces tumor incidence in HCV transgenic mice. (A) Tumor incidence in control,
FL-N/35 IkkbFlox/Flox and FL-N/35 IkkbDhep male mice as a function of age. All animals are of the same mixed C57Bl/6/C3H genetic background.
*p,0.02 (two sided Fisher’s exact test). (B) IKKb protein expression in wild type, FL-N/35IkkbF/F and FL-N/35 IkkbF/F: Alb-Cre (FL-N/35 IkkbDhep) mice.
(C) RT-qPCR analysis of NS5B mRNA expression in FL-N/35 and FL-N/35 IkkbDhep mice. Student’s test showed no significant differences between the
two groups.
doi:10.1371/journal.ppat.1003234.g005
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39- gccggaattatcatcccattcaaaagttctctttgaatgggatgataattccg-
gaaaaaagagctccttaa –59
ShLuc, the shRNA directed against luciferase, comes from
RNAi-Ready pSIRENRetroQ Retroviral Vector kit (Clontech)
Generation of NS5B catalytic mutant
The point mutation G317V [45]. was introduced in the GDD
motif of the NS5B gene by site-directed mutagenesis (QuikChange
II XL, Agilent Technologies), using the following primers :
59-GCTCGTGAACGTAGACGACCTTGTC-39, 59-GA-
CAAGGTCGTCTACGTTCACGAGC-39.
The specificity of the mutagenesis was verified by DNA
sequencing of the entire coding sequence.
Immunobloting
Western blots were performed as described previously [65].
Band intensities were quantified with the Gene Tools software
(SynGene). Polyclonal rabbit antibodies anti-LTb (ab 64835) and
anti-NS5B (ab 35586) were from Abcam (Cambridge, UK).
Polyclonal rabbit antibodies anti-p100/p52 (4882p) was from
Ozyme (Saint-Quentin, France). Mouse monoclonal antibodies
anti-IKKb (clone 10AG2, Upstate) and anti-CXCL10 were
respectively from Millipore (Temecula, CA, USA) and BD
Biosciences (Oxford, UK).
RNA isolation and analysis
Total RNA was isolated using an RNeasy Mini Kit (Qiagen,
Germantown, MD, USA) including DNase treatment to remove
possible genomic DNA contamination and used for first strand
cDNA synthesis with random hexamers. Analyses were performed
as described previously [65].
Histology
Mice were sacrificed with an overdose of pentobarbital
(Narconen, Basel, Switzerland) and perfused transcardially with
4% paraformaldehyde in phosphate-buffered saline (PBS). The
liver was removed, post-fixed and embedded in Tissue-Tek OCT
Compound. Sections of 4 mm were stained with haematoxylin and
eosin and then mounted in Eukitt.
Immunohistochemistry
Four micrometer sections were mounted on glass slides and
stained using ABC Vectastain system from Vector laboratory
(Burlingame, CA, USA). Monoclonal primary mouse antibodies
for mice samples were anti-Mac 2, anti CD3 from eBioscience
(San Diego, CA, USA) anti B220 from BD Biosciences (Oxford,
UK) and p65 from Santa Cruz Biotechnology (Heidelberg,
Germany). For human samples polyclonal rabbit antibodies anti-
LTb (ab 64835) was from Abcam (Cambridge, UK). Biotinylated
Figure 6. Upregulation of lymphotoxin signaling in HCV cellular models. Protein and RNA extracts from exponentially growing full-length
(Nneo/C-5B) replicon lines, the infectious HCV model and the corresponding control cell lines, Huh7 and Huh7.5.1, respectively, were analyzed by RT-
qPCR and by immunoblotting. (A) Analysis of LTa, LTb, LTbR and CXCL10 mRNA expression and representative protein expression of LTb in the Nneo/
C-5B replicon propagated in Huh7 cells and in JFH1-infected Huh7.5.1 cells (B) Representative immunoblots of 3 independent experiments are
shown. Where appropriate, results are presented as mean+/2 SEM of 3 separate experiments (*p,0.01, **p,0.001).
doi:10.1371/journal.ppat.1003234.g006
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secondary antibody was from Vector Laboratory (Burlingame,
CA, USA). Control experiments were done in the absence of the
primary antibody and were negative in all cases.
Immunofluorescence
Cells were fixed in 4% paraformaldehyde, permeabilized in
0.1% Triton X-100, rinsed in phosphate-buffered saline, blocked
with 1 mg/ml BSA and incubated with rabbit polyclonal anti-LTb
antibody from Abcam (Cambridge, UK) or with anti-p52 from
Santa Cruz Biotechnology (Heidelberg, Germany) for 2 hours
followed by anti-rabbit Alexa Fluor 488 for 1 hour. Samples were
mounted with Fluorosave (Calbiochem, La Jolla, CA, USA) and
analysed with a Zeiss fluorescent microscope equipped with a
digital camera (Axiocam, Carl Zeiss, Oberkochen, Germany).
Statistical analysis
Experiments were performed at least three times. Data are
presented either from a representative experiment or as mean
6 SEM. Comparisons between groups were analyzed by
Student’s t test or Wilcoxon matched-pairs signed rank test as
indicated.
Supporting Information
Figure S1 FACS analysis of intrahepatic myeloid, B, T,
NK and NKT cells from wild type and FL-N/35 mice.
Analyses were performed on FACS Canto II (BD Bioscience,
Oxford, UK) using following antibodies: CDK4-FITC; NK1.1-
PE; CD19-PrCP; CD3-PC7; CD11b-APC; CD8-AAF750. Stu-
dent’s test showed no significant differences for any of the cells
assayed.
(TIF)
Figure S2 Cytokine expression profiles in livers of FL-
N/35 and wild type mice. RNA extracted from livers bearing
no tumours in seven transgenic and seven wt mice was analyzed by
RT-qPCR for LTa, LTb, LTbR, TNFa, IL6, IL1b, IL18 (A) and
Figure 7. NS5B enzymatic activity is required for activation of lymphotoxin expression and signaling. (A) Expression of LTb protein in
exponentially growing Huh7 cells, Huh7 stably expressing NS5B (Huh7-NS5B) and Nneo/C-5B replicon (C-5B) (B) Expression of LTb protein in HepaRG
and HepaRG-NS5B doxycycline-inducible cells (HepaRG-iNS5B). (C) Expression of LTb protein in exponentially growing Huh7 cells and in Huh7 stably
expressing NS5B, treated with the NS5B polymerase inhibitor 29-C-Methylcytidine, as indicated. (D) Expression of LTb protein in HepaRG, HepaRG-
PMSCV, HepaRG-NS5B and HepaRG-NS5B G317V. (E) RT-qPCR analysis of LTa, LTb, LTbR and CXCL10 mRNA expression in Huh7 and Huh7-NS5B
treated or not by 29-C-Methylcytidine. 18S rRNA served as normalization standard. (F) Immunofluorescence analysis of p65 nuclear translocation in
Huh7 cells and Huh7-NS5B treated or not with 29-C-Methylcytidine. (G) Expression of p100, p52 and LTb proteins in Huh7 cells and Huh7 stably
expressing NS5B treated or not with 29-C-Methylcytidine. (H) RT-qPCR analysis of CXCL10 mRNA expression. Parental and NS5B-expressing Huh7 cells
were transduced with retroviral vectors encoding shRNA directed against p65, LTb or Firefly luciferase as control. Where appropriate, results are
presented as mean+/2 SEM of three separate experiments (student test, *p,0.01, **p,0.001).
doi:10.1371/journal.ppat.1003234.g007
HCV Polymerase Activates Lymphotoxin Signaling
PLOS Pathogens | www.plospathogens.org 9 March 2013 | Volume 9 | Issue 3 | e1003234
CCL2, CXCL10, CXCL1, CCL5 (B) mRNA and normalized to
18S rRNA. Student’s test showed no significant differences for any
of the assayed cytokines.
(TIF)
Figure S3 Expression profiles of pro-inflammatory
cytokines in FL-N/35 tumors. RNA extracted from FL-N/
35 tumors and corresponding peritumoral areas were analyzed by
RT-qPCR for IL6, IL18, TNFa, IL1b and normalized to 18S
rRNA. Numbers correspond to different animals studied. Results
were analyzed by Wilcoxon matched-pairs signed rank test.
(*p,0.05).
(TIF)
Figure S4 Expression profiles of IFNa and IFNb in FL-
N/35 tumors. RNA extracted from FL-N/35 tumors and
corresponding peritumoral areas were analyzed by RT-qPCR for
IFNa (A) and IFNb (B) and normalized to HPRT mRNA.
Numbers correspond to different animals studied. Results were
analyzed by Wilcoxon matched-pairs signed rank test and showed
no significant difference.
(TIF)
Figure S5 LTb expression in human hepatocellular
carcinoma. (A) RNA was extracted from frozen specimens of
human tumours and the corresponding non-tumoral liver
tissues. The level of LTb was assessed by quantitative RT-
PCR and normalized to 18S mRNA. (B) Immunohistochemical
staining of LTb (brown) in a healthy control liver (left panel)
and in a peritumoral (middle panel) region and HCC (right
panel) from the same HCV+ patient. PT = peritumoral,
T = tumoral.
(TIF)
Figure S6 LTb expression in cell lines stably expressing
individual HCV proteins. Huh7 cells were transduced with
retroviral vectors coding for myc-tagged HCV1b proteins NS3,
NS4A, core and NS5A, as indicated. Viral proteins expression was
revealed by immunoblotting with an anti-myc monoclonal
antibody.
(TIF)
Figure S7 p65 and LTb are efficiently silenced by their
cognate shRNA. NS5B-expressing and parental Huh7 cells were
transduced with retroviral vectors encoding shRNA for p65 (A) or
LTb (B) and protein expression was assayed by immunoblotting.
GAPDH served as a loading control.
(TIF)
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